Items Tagged ‘everolimus’

November 9th, 2017

Checkpoint Inhibitors Improve Outcomes of Renal Cell Cancer

By

Opdivo (nivolumab) a novel “checkpoint” inhibitor immunotherapy has been demonstrated to produce superior three year survival benefit for patients with previously treated advanced renal cell carcinoma (RCC).1 Treatment options for RCC continue to expand and are associated with improved outcomes. About Renal Cell Carcinoma Renal cell carcinoma accounts for more than 100,000 deaths worldwide each […]

View full entry

Tags: afinitor, checkpoint inhibitor, everolimus, immunotherapy, metastatic kidney cancer, News, opdivo, PD-1, Precision Cancer Medicine, Renal Cancer


June 19th, 2017

FDA Fast Track Designation Granted To CB-839 For Treatment Of Patients With Renal Cell Carcinoma

By

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CB-839 in combination with afinitor® (everolimus), for the treatment of patients with metastatic renal cell carcinoma who have received 2 or more prior lines of therapy.  CB-839 is a first-in-class, oral, selective, potent inhibitor of glutaminase being evaluated in Phase 1/2 clinical […]

View full entry

Tags: afinitor, Calithera Bioscience, CB-839, everolimus, kidney cancer, News, precision medicine, Renal Cancer, renal cell carcinoma


May 24th, 2016

Lenvima® Approved for Kidney Cancer

By

The United States Food and Drug Administration (FDA) has approved Lenvima® (lenvatinib) for the treatment of kidney cancer. The approval is for patients with advanced renal cell carcinoma who have received at least one prior therapy with an anti-angiogenic agent, and is to be used in combination with the standard agent Afinitor® (everolimus). Each year […]

View full entry

Tags: afinitor, everolimus, fda, General Renal Cancer, kidney cancer, lenvatinib, Lenvima, News, rcc, Renal Cancer, RTK


August 10th, 2015

Afinitor® Promising in Neuroendocrine Tumors Originating in Gastrointestinal Tract or Lungs

By

The drug Afinitor® (everolimus) is currently be studied in a Phase III clinical trial for patients with nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract or lungs. The trial is ongoing, but findings so far are promising: patients treated with Afinitor plus best supportive care appear to live longer without cancer progression than patients […]

View full entry

Tags: afinitor, everolimus, Gastric Cancer, General Lung Cancer, Lung Cancer, mtor, NET, neuroendocrine tumors, News, Recurrent Gastric Cancer, Stages III-IV Gastric Cancer